Tag: biotech

Antibody-drug conjugates: targeted cancer therapies coming of age

Bert-Jan Haijema Gert Barf CMC Antibody-drug conjugates, ADCs

Antibody-drug conjugates (ADCs) are currently at the forefront of the drug development revolution occurring in oncology delivering on the long-standing promise of a highly effective and selective cancer treatment. They are among the fastest-growing drug classes in oncology with a remarkable surge in marketing approvals in recent years. Nine ADCs were FDA approved from 2017 continue reading…

Patient-Driven Drug Development: Does Patient Involvement Truly Improve the Success Rates of New Treatments?

In recent years, the biotechnology industry has seen a transformative shift towards patient-driven drug development. At 3D-PharmXchange, we have experienced firsthand the impact that patient involvement can have on the development of new therapies. It has already been well described that patients bring a unique perspective that often reshapes the design of clinical trials. Their continue reading…